Moh’d Khushman, MD, discusses INCA33890’s mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer.
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.